Key facts
- This page summarizes Margaret Dugan's Form 4 filing for Schrodinger, Inc. (SDGR).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Mar 2025, 17:27.
Margaret Dugan - 03 Mar 2025 Form 4 Insider Report for Schrodinger, Inc. (SDGR)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- SDGR
- Reported as of
- 03 Mar 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Mar 2025, 17:27:54 UTC
- Prior SEC filing
- 16 Oct 2024
- Next SEC filing
- 22 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Donald Shum, as attorney-in-fact for Margaret Dugan
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Margaret Dugan filed Form 4 for Schrodinger, Inc. (SDGR) on 04 Mar 2025.
Change
- Previous filing in this sequence was filed on 16 Oct 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SDGR
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +12,500
- Change %
- +93%
- Price
- $0.000000
- Shares after
- 25,969
- Date
- 03 Mar 2025
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SDGR
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +50,000
- Change %
- Price
- $0.000000
- Shares after
- 50,000
- Date
- 03 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $21.24
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Grant of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on March 3, 2025 and will vest in equal installments on each of March 4, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continued service with the company.
Footnote F2
Includes 23,750 unvested RSUs.
Footnote F3
The option was granted on March 3, 2025. The shares underlying the option are scheduled to vest with respect to 25% of the shares on March 3, 2026 and the remainder are scheduled to vest in equal monthly installments through March 3, 2029.